Ana-MariaOrbaiMD

Rheumatology • Baltimore, MD

Rheumatoid Arthritis & Related, Spondyloarthropathy

Instructor of Medicine, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Orbai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Orbai's full profile

Already have an account?

Office
4940 Eastern Avenue
Bayview Medical Offices, Level 01 (G), Clinic 5
Baltimore, MD 21224
Phone+1 443-997-1552

Fax+1 410-550-1033

Education & Training

Johns Hopkins Bloomberg School of Public HealthMHS, Clinical Investigation, 2012 - 2013
Johns Hopkins UniversityFellowship, Rheumatology, 2010 - 2013
Johns Hopkins UniversityFellowship, Rheumatology, 2010 - 2012
Sinai Hospital of BaltimoreResidency, Internal Medicine, 2008 - 2010
Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Sinai Hospital of BaltimoreInternship, Internal Medicine, 2007 - 2008
Iuliu Hatieganu University of Medicine and PharmacyClass of 2004

Certifications & Licensure

FL State Medical License 2020 - Present
MD State Medical License 2013 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow American College of Rheumatology
Jerome L Greene Foundation Scholar Jerome L Greene Foundation, 2018
Scientist Development Award Rheumatology Research Foundation, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Join now to see all

Clinical Trials

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Start of enrollment: 2014 Dec 31
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Start of enrollment: 2016 Jun 27
Completed
Phase 4
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) Start of enrollment: 2017 Apr 27
Active, not recruiting
Phase 3
Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. Start of enrollment: 2017 May 18
Completed
Treatment Goals in Psoriatic Arthritis Start of enrollment: 2018 Dec 20
Completed
Join now to see all

Publications & Presentations

PubMed

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
Clementina López-Medina, Clémence Gorlier, Ana-Maria Orbai, Laura C Coates, Uta Kiltz
Rheumatology. 2025-01-03
SOX-5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women.
Ana-Maria Orbai, David Fiorentino, Jamie Perin, Erika Darrah, Qingyuan Yang
ACR Open Rheumatology. 2024-12-01
Composite Outcome Measures for Psoriatic Arthritis: OMERACT and 3 and 4 Visual Analog Scale Progress in 2023.
Ying Ying Leung, Dafna D Gladman, Ana-Maria Orbai, William Tillett
The Journal of Rheumatology. 2024-10-01

Press Mentions

The Management of Psoriatic Arthritis: A ReviewNovember 17th, 2024
Emerging and Novel Therapeutics in the Management of Psoriatic ArthritisApril 18th, 2022
How Psoriasis and Your Thyroid May Be LinkedNovember 18th, 2023

Professional Memberships

American College of Rheumatology - ACR
Member

Other Languages

Romanian, French

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ana-maria-orbai